These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

229 related articles for article (PubMed ID: 24935650)

  • 1. A recombinant adenovirus-based vector elicits a specific humoral immune response against the V3 loop of HIV-1 gp120 in mice through the "Antigen Capsid-Incorporation" strategy.
    Gu L; Krendelchtchikova V; Krendelchtchikov A; Oster RA; Fujihashi K; Matthews QL
    Virol J; 2014 Jun; 11():112. PubMed ID: 24935650
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Adenoviral vectors elicit humoral immunity against variable loop 2 of clade C HIV-1 gp120 via "Antigen Capsid-Incorporation" strategy.
    Gu L; Krendelchtchikova V; Krendelchtchikov A; Farrow AL; Derdeyn CA; Matthews QL
    Virology; 2016 Jan; 487():75-84. PubMed ID: 26499044
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Construction and characterization of a recombinant human adenovirus type 3 vector containing two foreign neutralizing epitopes in hexon.
    Xue C; Tian X; Li X; Zhou Z; Su X; Zhou R
    Virus Res; 2014 Apr; 183():67-74. PubMed ID: 24518297
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of HIV-1 envelope cytoplasmic tail on adenovirus primed virus encoded virus-like particle immunizations.
    Andersson AC; Ragonnaud E; Seaton KE; Sawant S; Folgori A; Colloca S; Labranche C; Montefiori DC; Tomaras GD; Holst PJ
    Vaccine; 2016 Oct; 34(44):5344-5351. PubMed ID: 27633665
    [TBL] [Abstract][Full Text] [Related]  

  • 5. HIV antigen incorporation within adenovirus hexon hypervariable 2 for a novel HIV vaccine approach.
    Matthews QL; Fatima A; Tang Y; Perry BA; Tsuruta Y; Komarova S; Timares L; Zhao C; Makarova N; Borovjagin AV; Stewart PL; Wu H; Blackwell JL; Curiel DT
    PLoS One; 2010 Jul; 5(7):e11815. PubMed ID: 20676400
    [TBL] [Abstract][Full Text] [Related]  

  • 6. First-in-human evaluation of a hexon chimeric adenovirus vector expressing HIV-1 Env (IPCAVD 002).
    Baden LR; Walsh SR; Seaman MS; Johnson JA; Tucker RP; Kleinjan JA; Gothing JA; Engelson BA; Carey BR; Oza A; Bajimaya S; Peter L; Bleckwehl C; Abbink P; Pau MG; Weijtens M; Kunchai M; Swann EM; Wolff M; Dolin R; Barouch DH
    J Infect Dis; 2014 Oct; 210(7):1052-61. PubMed ID: 24719474
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Using multivalent adenoviral vectors for HIV vaccination.
    Gu L; Li ZC; Krendelchtchikov A; Krendelchtchikova V; Wu H; Matthews QL
    PLoS One; 2013; 8(3):e60347. PubMed ID: 23555957
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Elicitation of broadly reactive antibodies against glycan-modulated neutralizing V3 epitopes of HIV-1 by immune complex vaccines.
    Kumar R; Tuen M; Liu J; Nàdas A; Pan R; Kong X; Hioe CE
    Vaccine; 2013 Nov; 31(46):5413-21. PubMed ID: 24051158
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Adenovirus-human immunodeficiency virus (HIV) envelope recombinant vaccines elicit high-titered HIV-neutralizing antibodies in the dog model.
    Natuk RJ; Chanda PK; Lubeck MD; Davis AR; Wilhelm J; Hjorth R; Wade MS; Bhat BM; Mizutani S; Lee S
    Proc Natl Acad Sci U S A; 1992 Aug; 89(16):7777-81. PubMed ID: 1502197
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Improving immunogenicity of HIV-1 envelope gp120 by glycan removal and immune complex formation.
    Kumar R; Tuen M; Li H; Tse DB; Hioe CE
    Vaccine; 2011 Nov; 29(48):9064-74. PubMed ID: 21945958
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Utilizing the antigen capsid-incorporation strategy for the development of adenovirus serotype 5-vectored vaccine approaches.
    Gu L; Farrow AL; Krendelchtchikov A; Matthews QL
    J Vis Exp; 2015 May; (99):e52655. PubMed ID: 25993057
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Antibody responses to prime-boost vaccination with an HIV-1 gp145 envelope protein and chimpanzee adenovirus vectors expressing HIV-1 gp140.
    Emmer KL; Wieczorek L; Tuyishime S; Molnar S; Polonis VR; Ertl HC
    AIDS; 2016 Oct; 30(16):2405-2414. PubMed ID: 27525550
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Enhanced Immune Responses to HIV-1 Envelope Elicited by a Vaccine Regimen Consisting of Priming with Newcastle Disease Virus Expressing HIV gp160 and Boosting with gp120 and SOSIP gp140 Proteins.
    Khattar SK; DeVico AL; LaBranche CC; Panda A; Montefiori DC; Samal SK
    J Virol; 2016 Feb; 90(3):1682-6. PubMed ID: 26581986
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Improved humoral and cellular immune responses against the gp120 V3 loop of HIV-1 following genetic immunization with a chimeric DNA vaccine encoding the V3 inserted into the hepatitis B surface antigen.
    Fomsgaard A; Nielsen HV; Bryder K; Nielsen C; Machuca R; Bruun L; Hansen J; Buus S
    Scand J Immunol; 1998 Apr; 47(4):289-95. PubMed ID: 9600309
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Vaccination of rhesus macaques with recombinant Mycobacterium bovis bacillus Calmette-Guérin Env V3 elicits neutralizing antibody-mediated protection against simian-human immunodeficiency virus with a homologous but not a heterologous V3 motif.
    Someya K; Cecilia D; Ami Y; Nakasone T; Matsuo K; Burda S; Yamamoto H; Yoshino N; Kaizu M; Ando S; Okuda K; Zolla-Pazner S; Yamazaki S; Yamamoto N; Honda M
    J Virol; 2005 Feb; 79(3):1452-62. PubMed ID: 15650171
    [TBL] [Abstract][Full Text] [Related]  

  • 16. HIV/AIDS Vaccine Candidates Based on Replication-Competent Recombinant Poxvirus NYVAC-C-KC Expressing Trimeric gp140 and Gag-Derived Virus-Like Particles or Lacking the Viral Molecule B19 That Inhibits Type I Interferon Activate Relevant HIV-1-Specific B and T Cell Immune Functions in Nonhuman Primates.
    García-Arriaza J; Perdiguero B; Heeney JL; Seaman MS; Montefiori DC; Yates NL; Tomaras GD; Ferrari G; Foulds KE; Roederer M; Self SG; Borate B; Gottardo R; Phogat S; Tartaglia J; Barnett SW; Burke B; Cristillo AD; Weiss DE; Lee C; Kibler KV; Jacobs BL; Wagner R; Ding S; Pantaleo G; Esteban M
    J Virol; 2017 May; 91(9):. PubMed ID: 28179536
    [TBL] [Abstract][Full Text] [Related]  

  • 17. V3-specific neutralizing antibodies in sera from HIV-1 gp160-immunized volunteers block virus fusion and act synergistically with human monoclonal antibody to the conformation-dependent CD4 binding site of gp120. NIH-NIAID AIDS Vaccine Clinical Trials Network.
    Montefiori DC; Graham BS; Zhou J; Zhou J; Bucco RA; Schwartz DH; Cavacini LA; Posner MR
    J Clin Invest; 1993 Aug; 92(2):840-7. PubMed ID: 8349820
    [TBL] [Abstract][Full Text] [Related]  

  • 18. An engineered mutant of HIV-1 gp120 formulated with adjuvant Quil A promotes elicitation of antibody responses overlapping the CD4-binding site.
    Ahmed FK; Clark BE; Burton DR; Pantophlet R
    Vaccine; 2012 Jan; 30(5):922-30. PubMed ID: 22142583
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Induction of Heterologous Tier 2 HIV-1-Neutralizing and Cross-Reactive V1/V2-Specific Antibodies in Rabbits by Prime-Boost Immunization.
    Townsley S; Mohamed Z; Guo W; McKenna J; Cleveland B; LaBranche C; Beaumont D; Shen X; Yates NL; Pinter A; Tomaras GD; Ferrari G; Montefiori DC; Hu SL
    J Virol; 2016 Oct; 90(19):8644-60. PubMed ID: 27440894
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Capsid display of a conserved human papillomavirus L2 peptide in the adenovirus 5 hexon protein: a candidate prophylactic hpv vaccine approach.
    Wu WH; Alkutkar T; Karanam B; Roden RB; Ketner G; Ibeanu OA
    Virol J; 2015 Sep; 12():140. PubMed ID: 26362430
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.